A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Latest Information Update: 22 Apr 2025
At a glance
- Drugs SV 001 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Shanghai Synvida Biotechnology
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 30 Mar 2025 to 30 Dec 2025.
- 17 Apr 2025 Planned primary completion date changed from 30 Nov 2024 to 30 Nov 2025.
- 22 Feb 2024 New trial record